

the sugar moiety, provided that whenever B, B' or B" is purine or deazapurine, it is attached at the N⁹-position of the purine or deazapurine, and whenever B, B' or B" is pyrimidine, it is attached at the N¹-position;

wherein A represents at least one component of a signalling moiety and consists of at least three carbon atoms;

wherein B and A are attached directly or through a linkage group, said linkage group not interfering substantially with the characteristic ability of B to hybridize with said target or of A to produce a detectable signal, wherein if B is purine, A is attached to the 8-position thereof, if B is deazapurine, A is attached to the 7-position thereof, and if B is pyrimidine, A is attached to the 5-position thereof; wherein m, n and p are integers, provided that m and p are not simultaneously 0 and provided further that n is never 0; and wherein z represents H- or HO-;

and detecting any signal associated with [target-bound compounds] said compounds bound to said target.

Claim 140, line 12, delete "N¹" and substitute therefore -N¹-; and at line 28, delete "for the cyclic moiety" and substitute therefore -form the cyclic moiety-.

REMARKS

Applicants request entry of the foregoing amendments to more particularly point out their invention. Support for the amendments to claim 125 appears in the specification at page 26, lines 26-29. The amendments to claim 140 are to correct typographical errors. None of these amendments introduce new matter.

Pursuant to 37 C.F.R. §§ 1.56 and 1.97, applicants make the following documents of record in this patent application.